Drug intelligence / Profile preview

RQ3027

Development stage: Phase 1
Lead developer: Walvax Biotechnology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RQ3027 is a bivalent mRNA-based vaccine candidate developed by Walvax Biotechnology for the prevention of COVID-19. The vaccine is designed to provide broad protection against evolving SARS-CoV-2 strains by incorporating mRNA sequences that encode the spike proteins of the Alpha and Beta variants, as well as the Omicron XBB.1.5 subvariant. Utilizing lipid nanoparticle (LNP) technology for intracellular delivery, RQ3027 aims to stimulate the host immune system to produce neutralizing antibodies and elicit a robust T-cell response. It has been evaluated in clinical trials as a booster dose in healthy adults who have previously received primary COVID-19 vaccinations to address waning immunity and the emergence of new variants.

Other names: bivalent mRNA vaccine (Alpha/Beta+Omicron XBB.1.5)

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on RQ3027.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RQ3027.

Explore the full profile